On March 28, 2021, the first national large-scale offline investment promotion conference exclusively hosted by Wuhan Emerson Life Technology will be held in Room M202, Hall N1, International Expo Center. This offline investment promotion conference relies on the 18th China International Inspection The Medical and Blood Transfusion Instruments and Reagents Expo (referred to as 'CACLP') as the background, with the establishment of the company's brand and the promotion of the company's products as the core, invited well-known experts to give academic lectures and market prospect analysis.
The 18th China International Laboratory Medicine and Blood Transfusion Instruments and Reagents Expo ('CACLP') will be held in Chongqing International Expo Center from March 28th to 30th, 2021. The conference is characterized by a large amount of information, high popularity, strong professionalism and large scale, and has played an irreplaceable role in the promotion, sales, transformation, promotion and cooperation of in vitro diagnostic products. Each year, the exhibition attracts nearly 100,000 domestic and foreign experts, scholars, entrepreneurs, production enterprises, distribution companies, investment banks, laboratory medicine workers, laboratory medicine workers, experts and scholars from colleges and universities and other fields. visit.
The future has come
While the IVD industry is facing unprecedented pressure in 2020, it also ushered in new opportunities. The raging of the new crown epidemic has made the IVD industry develop rapidly. On December 15, 2020, the International Agency for Research on Cancer released the latest cancer research data. The data shows that there will be about 19.3 million new cancer cases and about 10 million deaths worldwide in 2020. The data covers 185 countries and 36 different types of cancer. According to the International Agency for Research on Cancer, one in five people will develop cancer in their lifetime, and one in eight men and one in 11 women. , one person will die of cancer, and 50.6 million people will still be alive five years after being diagnosed with cancer. The cancer burden forecast data for 2040 uploaded by the International Agency for Research on Cancer on its website, Global Cancer Watch, shows that there will be 28.4 million new cancer cases worldwide in 2040, an increase of 47% compared with 2020. And the largest increase in cases occurred in countries with low or moderate levels of development.
The BCC RESEARCH website has released the global next-generation cancer diagnostics market report, which analyzes the development trends of the global cancer diagnostics market from 2020 to 2025. According to the report, in 2020, the global next-generation cancer diagnostics market is worth more than $6.2 billion, and is expected to witness significant growth over the forecast period, with the next-generation cancer diagnostics market valued at $16.7 billion by 2025. The report analyzes the development trend of the cancer diagnosis market in the next few years from the perspectives of technology, application fields, and enterprise layout. Such a huge market means that the market outlet for cancer diagnosis is accelerating!
'Ai Changkang' sincerely recruits agents nationwide
The future has come, China's early cancer screening market is on the eve of the outbreak! With the rising incidence and mortality of cancer in China, the Chinese people's awareness of healthy consumption and health management has been escalating, and the concept of early cancer screening has gradually gained popularity. The colorectal cancer screening market in China increased from RMB 2.5 billion in 2015 to RMB 3 billion in 2019, and is expected to further increase to RMB 19.8 billion in 2030. The survey shows that the penetration rate of colorectal cancer screening in China rose to 16.4% in 2019; in the same period, the penetration rate in the United States exceeded 80%; it can be seen that the colorectal cancer screening market is full of stars.
A case of early cancer was found, a life was saved, and a family was happy. Globally, the incidence of colorectal cancer ranks third among all malignant tumors, and the mortality rate ranks second. In my country, the situation of colorectal cancer is even more severe. The average age of onset is 21 years earlier than that in Western countries, and more than 80% of bowel cancer patients are 'late stage'. Due to the long course of colorectal cancer, which usually takes 5-10 years, seizing the golden early diagnosis stage is the most effective means to control the development of the disease. There are as many as 120 million people at high risk of bowel cancer in China, and fewer than 10 million colonoscopies are performed per year. Low patient compliance, difficult appointments, and long queues have severely restricted colonoscopy for colon cancer screening. Amisen stands out from time to time, and the representative product of the new generation of early detection technology for bowel cancer - 'Aichangkang®' came into being. The painless, non-invasive, home sampling method breaks the time and space limitations of traditional methods, and makes up for the constraints and deficiencies in the practical application of colonoscopy screening. With the implementation of the national '2030 Healthy China' plan outline, my country urgently needs convenient and efficient early detection products for bowel cancer to improve the compliance and coverage of bowel cancer screening, so that more families can be free from the pain of cancer!
Sincerely invite you to participate in the 'New Generation of Non-invasive Early Screening Products for Colon Cancer - Aichangkang® National Investment Promotion Conference' held by Wuhan Emerson Life Technology Co., Ltd. on March 28, 2021 from 10:00 am to 12:00 am! On the spot, we invited well-known experts and business leaders to give academic speeches on professional knowledge and the company's product investment policy. At the same time, we also set up interesting quiz and lottery sessions, and many awards such as ipad are waiting for you. take. We are waiting for you in Conference Room M202, Hall N1, Chongqing International Expo Center!